Trial Profile
A Randomized, Open labEled, muLticenter Trial for Safety and Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells Acute Myocardial infarction
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Autologous mesenchymal stem cell therapy Pharmicell (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms RELIEF
- Sponsors Pharmicell
- 10 Apr 2024 Planned End Date changed from 31 Dec 2023 to 31 Oct 2024.
- 10 Apr 2024 Planned primary completion date changed from 31 Aug 2022 to 31 Oct 2024.
- 10 Apr 2024 Status changed from recruiting to active, no longer recruiting.